MEDIGENE AG NA O.N. news, videos and press releases - Page 2
For more news please use our advanced search feature.
MEDIGENE AG NA O.N. - More news...
MEDIGENE AG NA O.N. - More news...
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
- Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
- Medigene to Present at Upcoming Conferences
- Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
- Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
- Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
- Medigene amends 2023 financial guidance
- Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
- Medigene Reports Financial Results and Corporate Update for Q3 2023
- Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
- Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
- Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
- Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
- Medigene AG to present at the Baader Investment Conference 2023
- Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference
- Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes
- Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types
- Medigene AG to present at the 8th CAR-TCR Summit in Boston
- Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update
- Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
- Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023
- Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies
- Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
- Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors
- Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs
- Medigene AG to participate at BIO International in Boston
- Medigene AG Expands Patent Portfolio for its End-to-End Platform
- Medigene AG to present at upcoming investor conferences
- Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment
- Medigene AG reports financial results and business update for Q1 2023
